Spectrum of Headaches Associated With SARS‐CoV‐2 Infection: Study of Healthcare Professionals by Porta-Etessam, Jesús et al.
1697
Research Submission
Spectrum of  Headaches Associated With SARS-CoV-2 
Infection: Study of  Healthcare Professionals
Jesús Porta-Etessam, MD, PhD ; Jordi A. Matías-Guiu, MD, PhD; Nuria González-García, MD;  
Patricia Gómez Iglesias, MD; Enrique Santos-Bueso, MD, PhD; Pedro Arriola-Villalobos, MD, PhD;  
David García-Azorín DM ; Jorge Matías-Guiu, MD, PhD
Background.—Series of patients with SARS-CoV-2 infection report headache in 6%-15% of cases, although some data 
suggest that the actual frequency is higher, and that headache is not associated with fever. No study published to date has ana-
lyzed the characteristics of headache in these patients.
Objective.—To analyze the characteristics of COVID-19 related headaches.
Methods.—We conducted a survey of Spaniard healthcare professionals who have been infected by SARS-CoV-2 and pre-
sented headache during the course of the disease. The survey addressed respondents’ medical history and headache characteristics, 
and we analyzed the association between both.
Results.—We analyzed the responses of a sample of 112 healthcare professionals. History of migraine was reported by 
20/112 (17.9%) of respondents, history of tension-type headache by 8/112 (7.1%), and history of cluster headache was reported 
by a single respondent; 82/112(73.2%) of respondents had no history of headache. Headache presented independently of fever, 
around the third day after symptom onset. The previous history of migraine was associated with a higher frequency of pulsating 
headache (20% in patients with previous migraine vs 4.3% in those with no history of migraine, P  =  .013).
Conclusion.—Headache is often holocranial, hemicranial, or occipital, pressing, and worsens with physical activity or head 
movements. Because the characteristics of the headache and the associated symptoms are heterogeneous in our survey, we sug-
gest that several patterns with specific pathophysiological mechanisms may underlie the headache associated with COVID-19.
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INTRODUCTION
In December 2019, the World Health Organization 
reported cases of pneumonia associated with a new 
coronavirus, SARS-CoV-2, in Wuhan (Hubei province, 
China); the associated disease (COVID-19) quickly 
became a global pandemic. Numerous hospital case 
series and observational studies have described the 
clinical characteristics of patients in symptomatic 
phases; headache is recorded among these symptoms. 
Meta-analysis of these studies shows that headache is 
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reported in 6%-15% of patients.1-8 All these data are 
from studies conducted in China; however, preliminary 
data from our setting suggest that approximately 60% 
of patients with COVID-19 presented with headache.8
While headache is a frequent symptom of infec-
tion, it can present independently of fever in patients 
with SARS-CoV-2; most case series report no associa-
tion between headache and fever. Despite this, no study 
assessing the presence of headache during the course 
of COVID-19 has analyzed the characteristics of the 
pain or the potential association with a personal his-
tory of headache. The accurate description of head-
ache characteristics associated with COVID-19 might 
be relevant in terms of the diagnosis, as headache may 
be the presenting symptom.9-11 In addition, considering 
that headache is present in patients with COVID-19, 
the differential diagnosis with other types of head-
aches (including primary headaches and headaches 
associated with personal protective equipment, PPE) is 
important in the current pandemic situation. We hy-
pothesized that headache associated with COVID-19 
infections may have some particular clinical character-
istics, which may be different in those patients with a 
previous history of migraine.
A key characteristic of this pandemic has been 
the exposure of healthcare professionals, as well as 
frequent situations of anxiety, which may promote 
the appearance of headache in the absence of infec-
tion.12 Headache is reported more frequently among 
healthcare professionals with SARS-CoV-2 infection 
(53%-57%) than in the case studies cited above, proba-
bly because healthcare professionals are better able to 
recognize symptoms.13,14 For these reasons, healthcare 
professionals with COVID-19 may constitute an ap-
propriate source for identifying the characteristics of 
headache during the clinical phase of the disease. In 
this study, we aimed to analyze the characteristics of 
headaches associated with COVID-19.
METHODS
Study Design.—We performed a descriptive, 
cross-sectional, observational study of the clinical 
characteristics of headache in healthcare profession-
als with clinically diagnosed and/or serologically con-
firmed SARS-CoV-2 infection, not requiring hospital 
admission, who presented headache. Clinical diagnosis 
included suggestive symptoms (fever, cough, short-
ness of breath, chills, muscle pain, sore throat, and 
new loss of taste or smell) and the clinical diagnosis 
by the Department of Workplace Health in each cen-
tre, which motivated the quarantine of the healthcare 
worker. Laboratory diagnosis included RT-PCR or se-
rological tests. Laboratory testing was not performed 
in all cases because the availability of tests at the on-
set of the pandemic was low, and cases requiring hos-
pital admission or with unclear diagnosis were priori-
tized. Participants were recruited amongst healthcare 
professionals included in an electronic information 
group about COVID-19. The survey was open to other 
professionals that acknowledge the study through 
word of mouth. Data were gathered using an anon-
ymous, self-administered online questionnaire. The 
questionnaire was accessible through Google Docs and 
sent to healthcare professionals by text message. The 
survey was voluntary, and participants did not receive 
any incentive. A total of 957 healthcare profession-
als with COVID-19 were invited, although the sur-
vey was restricted to those with headache. Healthcare 
professionals with clinical diagnosis of SARS-CoV-2 
infection, positive test findings for the virus, or under 
quarantine pending testing due to symptoms compati-
ble with infection were asked to complete the question-
naire. The questionnaire was available between 16 and 
18 April 2020 and responses were stored in a database. 
The questionnaire was completely anonymous. The 
study included healthcare professionals from the Re-
gion of Madrid. According to official sources, there 
were 194,416 cases of SARS-CoV-2 infection in Spain 
on that day.15
The questionnaire comprised 9 sections: (1) 
Demographic data, including age, sex, medical history, 
and risk factors. (2) Profession (physician, nurse, nurs-
ing assistant, other). (3) Use of  personal protective 
equipment (which may be associated with headache). 
(4) Headache characteristics (quality, location, ac-
companying symptoms, trigger factors). (5) Temporal 
pattern of  onset of  headache (concurrently with 
other symptoms of  infection; after the onset of  viral 
infection symptoms; predominant, with few other Conflict of Interest: None
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symptoms; and others [not classifiable]). (6) Treatment 
received for the infection. (7) Treatment received for 
headache. (8) Temporal pattern of  the resolution of 
headache. (9) Prior diagnosis of  primary headache, 
based on the diagnosis conducted by a primary phy-
sician or a neurologist, with the recommendation of 
use of  the International Classification of  Headache 
Disorders.16
The Ethics Committee from the Hospital Clinico 
San Carlos (Madrid, Spain) approved the research pro-
tocol (code 20/318-E). All participants gave written in-
formed consent. The study was reported according to 
the CHERRIES checklist.17
Statistical Analysis.—Statistical analysis was con-
ducted using SPSS Statistics 20. Descriptive data are 
shown as number (percentage) or mean  ±  standard 
deviation. Kolmogorov-Smirnov test was used to 
check the normal distribution of quantitative vari-
ables. Data were analyzed for the total group and for 
subgroups of individuals with positive test results for 
SARS-CoV-2 and those diagnosed clinically. Chi-
squared test was used to evaluate the association be-
tween categorical variables. A P value <.05 was con-
sidered statistically significant. A P value between 
.05 and .10 was considered a trend toward significance. 
Primary analyzes were about the characteristics of 
headache. Secondary analyzes investigated the poten-
tial influence of the previous history of migraine in the 
headache characteristics during COVID-19 infection. 
No statistical power calculation was conducted pri-
or to the study, and the sample size was based on the 
available data.
RESULTS
We received 112 responses to the questionnaire; 
78/112 respondents (69.6%) were physicians, 11/112 
(9.8%) were nurses, 8/112 (7.1%) were nursing assis-
tants, and 15/112 (13.4%) worked in other roles. The 
completion rate was 100%. The majority was diag-
nosed clinically; polymerase chain reaction (PCR) 
or serological confirmation was reported in 47.3% 
of cases. The ratio of women to men was 4.3:1; the 
mean age of the sample was 43.4 ± 11.4 years; 5/112 
individuals (4.5%) presented arterial hypertension; 
15/112 (13.4%) had dyslipidemia; and none had dia-
betes or had undergone any neurosurgical procedure. 
Eighty-three respondents (74.1%) had used PPE, with 
60/112 (53.6%) using it throughout or for more than 
half  of their shift. Sixteen individuals (14%) had been 
treated for COVID-19. Regarding personal history of 
headache, 20/112 (17.9%) reported migraine, 8/112 
(7.1%) reported tension-type headache, and 1 reported 
cluster headache. No cases of trigeminal neuralgia or 
other primary headaches were reported. The remain-
ing 83 respondents did not report history of headache 
(Table 1).
Regarding the presentation and characteristics of 
headache, the meantime from onset of  viral infection 
symptoms to the onset of  headache was 3.9 ± 6.0 days; 
temperature was below 37.5ºC at the time of  headache 
onset in 99/112 cases (88.4%). Headache was hemi-
cranial in 52/112 cases (46.0%), holocranial in 48/112 
(42.5%), and occipital in 20/112 (17.7%). Pain was 
Table 1.—Data From Our Sample of  Survey Respondents 
on Demographic Variables, History of  Headache, the 
Use of  Personal Protective Equipment, and Serological 
Confirmation of  SARS-CoV-2 Infection
N = 112
Demographic variables
Age, mean (SD) 43.4 (11.4)
Sex (females) N(%) 91 (81.3%)
History of arterial hypertension 5 (4.5%)
History of diabetes mellitus 0
History of dyslipidemia 15 (13.4%)




Nursing assistant 8 (7.1%)
Other 15 (13.4%)
History of headache 29 (25.9%)
Migraine 20 (17.9%)
Tension-type headache 8 (7.1%)
Cluster headache 1 (0.9%)
Trigeminal neuralgia 0
Other primary headaches 0
PPE use 83 (74.1%)
Occasional 23 (20.5%)
Over 50% of the time 27 (24.1%)




Data are expressed as numbers and percentages of patients, 
unless otherwise indicated.
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described as pressing in 90/112 cases (80.4%), stab-
bing in 12/112 (10.7), and pulsating in 8/112 (7.4%); 2 
(1.8%) individuals described electric-shock-like pain. 
Twenty-five respondents presented some autonomic 
symptoms over the course of  the headache (rhinor-
rhea, tearing, or palpebral ptosis). Pain was exacer-
bated by physical activity in 57/112 cases (50.9%), by 
head movements in 52/112 (46.4%), and by both in 
67/112 (60%). Phonophobia and photophobia were 
reported by 46/112 and 32/112 individuals (41.0% 
and 28.6%, respectively), and 11/112 respondents 
(9.8%) reported osmophobia. Nausea was recorded 
in 21 cases (18.7%) and vomiting in 4/112 (3.6%). No 
respondent reported trigger points, but 5/112 (4.4%) 
reported allodynia. Aura was not reported in any 
case. Forty-four respondents (39.3%) attributed head-
ache to PPE use; 25% of  this group had a history of 
migraine (Table 2).
Table  3 compares the clinical characteristics of 
headache in individuals with and without a history of 
migraine. Respondents with history of migraine more 
frequently reported exacerbation with activity, nausea, 
and vomiting; none of these differences were statisti-
cally significant. Osmophobia and phonophobia were 
more frequent in the group with a history of migraine 
(P = .091 and P = .058, respectively); patients with a 
history of migraine did show a higher frequency of 
pulsating pain (20% in patients with previous migraine 
vs 4.3% in those with no history of migraine, P = .013). 
Sixty participants (53%) used PPE for at least half  of 
their shift; 44/60 of them (73%) attributed headache 
to PPE use, of whom 11/44 (25%) had a history of 
migraine.
DISCUSSION
We consider healthcare professionals to be an ap-
propriate population for analyzing clinical descrip-
tions of headache in this context, which would be less 
straightforward in other patient populations. The low 
rate of PCR and serology testing is explained by gov-
ernment recommendations that testing should not be 
performed in patients with symptoms indicative of in-
fection. Our main conclusion is that the infection can 
trigger headache in patients without a history of fre-
quent headache: 74.1% of our sample had no history 
of primary headache. Headache may be explained by 
several factors, including psychological factors or by 
the action of the virus itself. Headache was not associ-
ated with high fever, as is observed for other infectious 
processes: temperature was below 37ºC in 88.4% of 
cases. Pain onset typically occurred over 3 days after the 
onset of viral symptoms (ie, fever, cough, muscle pain, 
etc.); this may suggest that headache was mediated by 
Table 2.—Headache Characteristics (Duration, Location, 
Quality, and Association With the Use of  Personal 









Headache has not resolved 16 (15.0%)
Time (days) between the onset of viral infection 





Both eyes 38 (33.6%)
Occipital 20 (17.7%)
Frontal, unilateral 27 (23.9%)
Periorbital, unilateral 8 (7.1%)
Facial, unilateral 2 (1.8%)





Electric-shock-like, continuous 1 (0.9%)
Electric-shock-like, brief 1 (0.9%)
Characteristics
Exacerbated with activity 57 (50.9%)







Causes wakening 31 (27.7%)





Headache attributed to PPE use 44 (39.3%)
Data are expressed as the numbers and percentages of patients, 
unless indicated otherwise.
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the virus itself. The choice of healthcare professionals 
has several advantages for the aims of this study. First, 
the incidence of COVID-19 in healthcare workers has 
been high. Second, we used a questionnaire that was 
filled by the participant. Thus, better knowledge about 
symptoms is probably more necessary than when a 
questionnaire is administered by trained personnel. 
And third, participants were very motivated to par-
ticipate in the study, which favored the participation 
and the full completion rate of the questionnaire by 
all cases.
Our study found a noticeable heterogeneity of 
associate symptoms in headache during COVID-19. 
However, most common characteristics were the ho-
locranial, hemicranial, or occipital location, pressing, 
and the worsening with head movements or physical 
activity. The comparison of  headache characteristics 
between individuals with and without a history of 
migraine is of  particular interest, and suggests that 
some characteristics may be modulated by the previ-
ous history of  migraine. The percentage of  individu-
als reporting a history of  migraine is consistent with 
published epidemiological data for Spain.18,19
Although our study is not designed to discriminate 
between subtypes of headache, several main causes of 
headache could be distinguished from a pathophysio-
logical perspective:
1. In a first group, PPE use may play a role: This 
type of headache has previously been described,20 
and is included in the International Classification of 
Headache Disorders as “probable external-compres-
sion headache” (4.6.3.1). Pain is typically pressing, 
with variable location, and presents in half of 
individuals who use PPE. In this regard, in our 
study, individuals without a history of migraine 
more frequently attributed headaches to PPE use.20
2. A second group may present with a less specific, press-
ing headache without accompanying symptoms.
3. A third group may include those individuals with his-
tory of migraine (or other primary headaches) who 
presented headache compatible with their medical 
history; if  migraine, this group more frequently pre-
sented exacerbation with physical activity, nausea, 
vomiting, phonophobia, osmophobia, and photo-
phobia. Pulsatile pain presented a significant asso-
ciation with history of migraine (P =  .013). This is 
consistent with a recent study about headaches asso-
ciated with PPE, in which worsening of pre-existing 
headaches was observed with the use of PPE.20
4. Finally, the fourth group accounts for those indi-
viduals who we consider may present with headache 
secondary to SARS-CoV-2 infection. In this group, 
pain may be exacerbated with activity and head 
movement; may be holocranial or hemicranial; and 
Table 3.—Characteristics of  Headache Associated With COVID-19 in Respondents With and Without a History of  Migraine
N = 112 Migraine (N = 20) No Migraine (N = 92) χ2 P value
Male/female (% of females) 1/19 (95%) 20/72 (78.3%) 3.81 .115
Exacerbated with activity 12 (60%) 45 (48.9%) 0.80 .369
Exacerbated with head movement 10 (50%) 42 (45.7%) 0.12 .724
Nausea 6 (30%) 15 (16.3%) 2.02 .155
Vomiting 2 (10%) 2 (2.2%) 2.23 .146
Phonophobia 12 (60%) 34 (37.0%) 3.60 .058
Photophobia 8 (40%) 24 (26.1%) 1.55 .212
Osmophobia 4 (20%) 4 (4.3%) 2.84 .091
Trigger points 0 0 — —
Causes wakening 7 (35%) 24 (26.1%) 0.65 .420
Autonomic symptoms 2 (10%) 20 (21.5%) 1.43 .231
Allodynia 2 (10%) 3 (3.2%) 1.74 .185
Pulsating 4 (20%) 4 (4.3%) 6.06 .013*
Pressing 14 (70%) 76 (81.7%) 1.65 .198
Stabbing 2 (10%) 10 (10.7%) 0.01 .909
*Statistically significant at P value <.05.
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may be accompanied by phonophobia and less fre-
quently by photophobia, nausea, or vomiting.
This latter type of headache is of particular interest 
because exacerbation with effort/head movements and 
the presence of photo-/phonophobia are highly sugges-
tive of meningeal inflammation.21 Although evidence is 
still limited, this observation is relevant as it may show 
the potential spread of the virus to the central nervous 
system,22-24 which has been demonstrated in CSF in en-
cephalitis and in brain tissue in postmortem pathologi-
cal examination.25-27 Cases have also been reported of 
patients presenting SARS-CoV-2 RNA in the cerebro-
spinal fluid and magnetic resonance imaging findings of 
meningeal contrast uptake.28 The virus may reach the 
cerebrospinal fluid through the hematogenous route; 
however, given the prevalence of olfactory and gusta-
tory alterations in patients with COVID-19, it has also 
been suggested that it may be transported through the 
olfactory system,29 as olfactory endothelial cells express 
the ACE2 receptor.30 The virus may also reach the cen-
tral nervous system by crossing the cribriform plate.31 
Another hypothesis is that the virus may also enter the 
central nervous system through the trigeminovascular 
system; this is consistent with the fact that 22% of re-
spondents in our sample reported autonomic symptoms. 
Coronaviruses are neurotropic and are able to access 
and remain in the central nervous system,32 spreading 
through trans-synaptic and axonal transport.33
Finally, headache characteristics may be associated 
with inflammatory mechanisms. SARS-CoV-2 acts on 
both the innate and the adaptive immune responses,34 
and can cause the so-called cytokine storm, character-
ized by the release of chemokines and such cytokines 
as IL-6,35,36 which are also associated with pain.37 
Because cytokine storm presents during the clinical 
course of the infection, this may suggest that the pat-
tern of headache could change during the disease.
Further studies specifically designed to evaluate the 
number of latent groups of individuals according to the 
pattern of symptoms and the characteristics of headache 
are necessary. In this regard, larger sample sizes, more 
comprehensive questionnaires, and multivariate statisti-
cal analysis or clustering algorithms would be required.
An interesting point is the high percentage of 
females in our study. On the one hand, in our 
setting the percentage of females amongst healthcare 
professionals is high. On the other hand, sex matters in 
COVID-19, in which males are more prone to present 
severe pulmonary disorders, while headache or anos-
mia may be more frequent in females.38
Our study does present some limitations. The low 
mean age of our respondents is mainly due to the fact 
that we sampled a population of actively employed 
professionals, who contracted the virus through direct 
contact with patients, leading to mild-to-moderate 
symptoms. Pre-existing headache was defined accord-
ing to the medical diagnosis with the recommendation 
of the use of ICHD-3 criteria, but headache diagno-
sis was not confirmed as a part of the research pro-
tocol. However, because participants are healthcare 
professionals with easier access to specialized care, the 
percentage of misdiagnosis of type of headache is prob-
ably low than in other populations. We cannot specify 
the response rate of our survey, because the survey was 
focused only on professionals that presented headache, 
but the invitation was general for healthcare profes-
sionals with COVID-19. Since we invited a total of 957 
subjects and considering the frequency of headache re-
ported in the case series of patients with COVID-19,8 
the response rate would be high, but we cannot reliably 
estimate it. In addition, the questionnaire has not been 
previously validated against a clinical diagnosis based 
on standardized criteria. However, the questionnaire 
was developed by consensus by a multidisciplinary team 
of neurologists and ophthalmologists, with experience 
in the development of questionnaires for epidemiology 
in migraine.18 Few respondents had undergone PCR or 
serology testing because of a Government decision at 
the onset of the pandemic; however, headache has been 
reported at similar frequencies among patients who 
have and have not undergone these tests.39 In any case, 
the analysis of other patient groups may confirm the 
association of these types of headache with COVID-19. 
Furthermore, prospective studies are required to con-
firm our findings.
In conclusion, our study analyzed the character-
istics of headache in the context of SARS-CoV-2 in-
fection. Headache is often holocranial, hemicranial, 
or occipital, pressing, and worsens with physical ac-
tivity or head movements. Because the characteristics 
of the headache and the associated symptoms are 
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heterogeneous in our survey, we suggest the possibil-
ity that several patterns with specific pathophysiologi-
cal mechanisms may underlie the headache associated 
with COVID-19.
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